Target intelligence / Profile preview

Long intergenic non-protein coding RNA 402 (LINC00402)

Target
LINC00402
Molecular classification
Long non-coding RNA (lncRNA)
01

Overview

Long intergenic non-protein coding RNA 402 (LINC00402) is a conserved long non-coding RNA (lncRNA) gene strongly enriched in T cells and cortical neurons, with higher expression levels noted in human and murine T cells. LINC00402 plays a regulatory role in T-cell responses, specifically augmenting T cell proliferation under allogeneic stimulation, modulating ERK1/2 kinase activity, FOS nuclear localization, and IL-2/Egr-1 expression following T cell receptor engagement, and inversely correlating with T cell activation status. Its expression is influenced by immunosuppressive drugs in transplantation settings, and lower levels are associated with higher risk of acute graft-versus-host disease. LINC00402 additionally participates in ceRNA networks relevant to cancer progression and prognosis. It is a potential therapeutic and prognostic target in immune-related diseases and multiple cancer types, yet direct drug interactions have not been described to date.

Other names
LINC00381LOC105370259Long intergenic non-protein coding RNA 381LINC00402hCG1820717
02

Mechanism of action

Modulation of immune cell function by influencing ERK1/2 signaling, FOS nuclear accumulation, and IL-2/Egr-1 expression after T cell receptor engagement; Regulation of gene expression via competitive endogenous RNA (ceRNA) networks affecting cancer pathways.

03

Biological functions

Regulation of T-cell activation and proliferationModulation of graft-versus-host disease risk (GVHD)Regulation of immune response in the context of transplantationPutative oncogenic or tumor suppressor roles through ceRNA networks
04

Disease associations

Cancer (colon cancer, metastatic melanoma, head and neck squamous cell carcinoma)Immune disorders (graft-versus-host disease, transplantation immunology)Potential role in chronic graft-versus-host disease
05

Safety considerations

None directly reported for therapeutic targeting; safety considerations in clinical contexts would relate to immune modulation and cancer implications
06

Biomarkers

Lower LINC00402 abundance as a biomarker for increased risk of acute graft-versus-host disease following transplantationCancer prognosis (prognostic biomarker in various tumor types)

Beyond the preview

Go deeper on Long intergenic non-protein coding RNA 402 (LINC00402).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Long intergenic non-protein coding RNA 402 (LINC00402).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call